PCSK9
Sort by:
Complex Coronary Cases
Lp(a): The New Kid on the Block
FEATURING
Pam Taub
- 2,635 views
- August 31, 2023
- 21
Complex Coronary Cases
LDL-c Reduction: How Low Can You Go?
FEATURING
Philippe Gabriel Steg
- 1,374 views
- August 31, 2023
- 14
Complex Coronary Cases
Eliminating Coronary Artery Disease
FEATURING
Marc Sabatine
- 1,203 views
- August 31, 2023
- 10
Canadian Collaborative Research Network
Approaching a Decade of PCSK9 Inhibition: Effects on CV Mortality
FEATURING
Milan Gupta
- 405 views
- July 26, 2023
- 2
Canadian Collaborative Research Network
Non-Statin Therapies for Elevated LDL-C: The Role of Inclisiran (and Other Therapeutics)
FEATURING
Jacques Genest
- 872 views
- July 26, 2023
- 5
Canadian Collaborative Research Network
Lp(a): When to Measure it and What to Do About it
FEATURING
Michelle O'Donoghue
- 15,738 views
- July 26, 2023
- 96
Canadian Collaborative Research Network
Has the Time Come to Treat Inflammation to Improve Cardiovascular Outcomes? (Yes!)
FEATURING
Paul Ridker
- 1,418 views
- July 26, 2023
- 10
Canadian Collaborative Research Network
State of the Heart 2023 Session 2 Panel Discussion
- 69 views
- July 26, 2023
- 1
Scripps Health
Lipids Update: Overview of Current Guidelines for Lipid Management
FEATURING
David Cork
- 1,734 views
- June 14, 2023
- 7
Jefferson Health
Update on Lipids: Current Options for Lowering LDL to Reduce CV Risk
FEATURING
Adam Cohen
- 4,103 views
- April 24, 2023
- 34
Houston Methodist DeBakey Heart and Vascular Center
Treatment of Lipids in 2023: Where Are We Now and Where Are We Going?
FEATURING
Christie Ballantyne
- 4,205 views
- April 5, 2023
- 18
The Texas Heart Institute
The 2022 ACC Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour
FEATURING
Christie Ballantyne
- 2,126 views
- February 8, 2023
- 9
The North American Thrombosis Forum (NATF)
Current Treatments for LDL Lowering — and Why Patient Access Is So Important
- 733 views
- January 26, 2023
- 1
The North American Thrombosis Forum (NATF)
Recent Cholesterol Guidelines and Integration into Clinical Practice
- 14,536 views
- January 26, 2023
- 38
The North American Thrombosis Forum (NATF)
Identifying Patients Who Would Benefit from PCSK9 Inhibitors
- 466 views
- January 26, 2023
- 1
The Texas Heart Institute
Lipid Lowering Therapies: Where Did We Start, Where We Are Now and What the Future Holds
FEATURING
Salim Virani
- 5,541 views
- January 5, 2023
- 36
Top Ten Topics in Clinical Cardiology 2022
Panel Discussion: Genetic Testing and Lipid Management
- 31 views
- November 21, 2022
Top Ten Topics in Clinical Cardiology 2022
What’ll be New in Lipid Management in 2023? Rethinking the Paradigms
FEATURING
Robert Rosenson
- 3,193 views
- November 21, 2022
- 10
Houston Methodist DeBakey Heart and Vascular Center
How to Choose from Established and Emerging Lipid Lowering Therapies
FEATURING
Christie Ballantyne
- 553 views
- November 15, 2022
- 2
AHA 2022 Conference Coverage
AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl
FEATURING
Nicholas Marston
- 11,849 views
- November 15, 2022
- 50
AHA 2022 Conference Coverage
AHA 2022: Emerging RNA Therapeutics for Lowering Serum LP(a)
FEATURING
Peter Toth
- 951 views
- November 14, 2022
- 3
Canadian Collaborative Research Network
FOURIER Ole Study: What Are the Long-Term Safety Data for PCSK9 Inhibitors?
FEATURING
Milan Gupta
- 279 views
- September 28, 2022
- 1
American College of Cardiology
TCT 2022: PCSK9 Inhibition, FAVOR III China, and SCAAR Studies
- 14 views
- September 20, 2022